Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
暂无分享,去创建一个
M. Chesselet | O. Rascol | I. McKeith | J. Attems | B. Mollenhauer | A. Antonini | H. Soreq | L. Stefanis | T. Outeiro | V. Bonifati | J. Hardy | M. Schlossmacher | R. Alcalay | Darren J. Moore | Francisco Cardoso | J. Ferreira | Graziella Madeo
[1] D. Arkadir,et al. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort , 2023, Movement disorders : official journal of the Movement Disorder Society.
[2] D. Hernandez,et al. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease , 2022, medRxiv.
[3] Yen F. Tai,et al. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort , 2022, npj Parkinson's Disease.
[4] T. Hatano,et al. Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease , 2022, Movement disorders clinical practice.
[5] H. Soreq,et al. Cerebrospinal fluid and blood profiles of transfer RNA fragments show age, sex and Parkinson’s disease-related changes , 2022, bioRxiv.
[6] T. Feng,et al. Oral Mucosa Derived α−Synuclein as a Potential Diagnostic Biomarker for Parkinson′s Disease , 2022, Frontiers in Aging Neuroscience.
[7] G. Disanto,et al. Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease , 2021, NPJ Parkinson's disease.
[8] James E. Tomkins,et al. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease , 2021, Annals of neurology.
[9] Alan J. Thomas,et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[10] A. Kakita,et al. Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations , 2021, Movement disorders : official journal of the Movement Disorder Society.
[11] K. Jellinger,et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study , 2021, Acta Neuropathologica.
[12] A. Singleton,et al. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression , 2020, Movement disorders : official journal of the Movement Disorder Society.
[13] M. Farrer,et al. Neuropathological findings in PINK1-associated Parkinson's disease. , 2020, Parkinsonism & related disorders.
[14] A. Singleton,et al. Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort , 2020, Frontiers in Neurology.
[15] A. Singleton,et al. Characterization of Recessive Parkinson Disease in a Large Multicenter Study , 2020, Annals of neurology.
[16] C. B. Sanz-Morère,et al. Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.
[17] E. Valente,et al. PINK1 and Parkin: The odd couple , 2020, Neuroscience Research.
[18] A. Kriško,et al. SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration , 2020, Movement disorders : official journal of the Movement Disorder Society.
[19] K. Nilsson,et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy , 2020, Nature.
[20] E. Gerhardt,et al. Synucleinopathies: Where we are and where we need to go , 2020, Journal of neurochemistry.
[21] Alan J. Thomas,et al. Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[22] P. Lockhart,et al. Distribution of Parkinson’s disease associated RAB39B in mouse brain tissue , 2019, Molecular Brain.
[23] J. Trojanowski,et al. Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease , 2019, Acta Neuropathologica Communications.
[24] K. Marder,et al. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. , 2019, Parkinsonism & related disorders.
[25] Sebastian Heinzel,et al. Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[26] T. Outeiro,et al. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies , 2019, Journal of neurochemistry.
[27] J. Attems,et al. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions , 2019, Journal of neurochemistry.
[28] B. Thelma,et al. Expanding the canvas of PRKN mutations in familial and early-onset Parkinson disease. , 2019, Parkinsonism & related disorders.
[29] E. Sidransky,et al. Glucocerebrosidase and its relevance to Parkinson disease , 2019, Molecular Neurodegeneration.
[30] K. Jellinger. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders , 2019, Journal of Neural Transmission.
[31] C. Jack,et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.
[32] P. Calabresi,et al. Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[33] A. Strafella,et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System , 2019, Alzheimer's & Dementia.
[34] Claudio Soto,et al. Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[35] T. Simuni,et al. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. , 2019, Parkinsonism & related disorders.
[36] Yinzhou Wang,et al. Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson’s Disease , 2019, Front. Aging Neurosci..
[37] C. Tanner,et al. Reproducibility of data-driven Parkinson's disease subtypes for clinical research. , 2018, Parkinsonism & related disorders.
[38] N. Hattori,et al. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations , 2018, Acta neuropathologica communications.
[39] I. König,et al. Genotype‐phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review , 2018, Movement disorders : official journal of the Movement Disorder Society.
[40] A. Brice,et al. The genetic landscape of Parkinson's disease. , 2018, Revue neurologique.
[41] C. Adler,et al. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4) , 2018, Journal of neuropathology and experimental neurology.
[42] T. Postmus. Genetics of Parkinson's disease , 2018 .
[43] E. Tolosa,et al. Lack of central and peripheral nervous system synuclein pathology in R1441G LRRK2-associated Parkinson’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[44] Z. Gan-Or,et al. GBA-Associated Parkinson’s Disease and Other Synucleinopathies , 2018, Current Neurology and Neuroscience Reports.
[45] I. König,et al. Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review , 2018, Movement disorders : official journal of the Movement Disorder Society.
[46] K. Marder,et al. Application of the Movement Disorder Society prodromal criteria in healthy G2019S‐LRRK2 carriers , 2018, Movement disorders : official journal of the Movement Disorder Society.
[47] Norbert Schuff,et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort , 2018, Movement disorders : official journal of the Movement Disorder Society.
[48] M. Stamelou,et al. Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD , 2018, Neurology.
[49] B. Ritz,et al. Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease , 2018, JAMA neurology.
[50] K. Marder,et al. Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.
[51] A. Schapira,et al. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[52] C. Franceschi,et al. Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis , 2018, Free radical biology & medicine.
[53] J. Del-Aguila,et al. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels , 2017, BMC Neurology.
[54] S. Schneider,et al. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.
[55] J. Ferreira,et al. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson’s disease , 2017, Scientific Reports.
[56] R. Nunes,et al. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2‐related Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[57] K. Marek,et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease , 2017, Journal of Neuroinflammation.
[58] A. Puschmann. New Genes Causing Hereditary Parkinson’s Disease or Parkinsonism , 2017, Current Neurology and Neuroscience Reports.
[59] R. Postuma,et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts , 2017, Movement disorders : official journal of the Movement Disorder Society.
[60] Nicholas W Wood,et al. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.
[61] A. Dagher,et al. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.
[62] R. Barker,et al. Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases , 2017, Parkinsonism & related disorders.
[63] J. Attems. The multi-morbid old brain , 2017, Acta Neuropathologica.
[64] J. Attems,et al. Interactions of pathological proteins in neurodegenerative diseases , 2017, Acta Neuropathologica.
[65] Oury Monchi,et al. The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward , 2017, Movement disorders : official journal of the Movement Disorder Society.
[66] N. Bouslam,et al. LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease , 2017, Parkinson's disease.
[67] B. Mollenhauer,et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.
[68] M. Stamelou,et al. Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. , 2017, Parkinsonism & related disorders.
[69] M. Esiri,et al. Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.
[70] M. Stamelou,et al. Motor and Nonmotor Features of Carriers of the p.A53T Alpha‐Synuclein Mutation: A Longitudinal Study , 2016, Movement disorders : official journal of the Movement Disorder Society.
[71] G. Halliday,et al. Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers , 2016, Movement disorders : official journal of the Movement Disorder Society.
[72] I. Alonso,et al. DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. , 2016, Brain : a journal of neurology.
[73] Simon C. Potter,et al. Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. , 2016, American journal of human genetics.
[74] Günther Deuschl,et al. MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[75] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[76] Jean-François Gagnon,et al. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.
[77] A. Desautels,et al. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.
[78] S. Lehéricy,et al. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry , 2015, Movement disorders : official journal of the Movement Disorder Society.
[79] Carlos Ortiz-de-Solorzano,et al. Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[80] A. Schapira. Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.
[81] T. Simuni,et al. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? , 2015, Neurodegenerative Diseases.
[82] Zuzana Walker,et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials , 2014, BMJ Open.
[83] W. Chung,et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. , 2014, JAMA neurology.
[84] Ludovico Minati,et al. Substantia nigra in Parkinson’s disease: a multimodal MRI comparison between early and advanced stages of the disease , 2014, Neurological Sciences.
[85] J. Ioannidis,et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants , 2012, Journal of Medical Genetics.
[86] A. Kupsch,et al. Changes in Clinical Management and Diagnosis following DaTscan™ SPECT Imaging in Patients with Clinically Uncertain Parkinsonian Syndromes: A 12-Week Follow-Up Study , 2012, Neurodegenerative Diseases.
[87] J. Hardy,et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations , 2012, Neurobiology of Aging.
[88] W. F. Abdo,et al. CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.
[89] P. Spano,et al. Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease , 2011, PLoS ONE.
[90] Janel O. Johnson,et al. Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α‐synuclein triplication (Iowa kindred) , 2011, Movement disorders : official journal of the Movement Disorder Society.
[91] Yu Wang,et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.
[92] B. Mollenhauer,et al. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.
[93] C. Sampaio,et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.
[94] P. Pástor,et al. PINK1-linked parkinsonism is associated with Lewy body pathology. , 2010, Brain : a journal of neurology.
[95] D. Dickson,et al. Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.
[96] Z. Wszolek,et al. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.
[97] Angelo Antonini,et al. Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy , 2008, Movement disorders : official journal of the Movement Disorder Society.
[98] B. Oostra,et al. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population , 2008, Neurogenetics.
[99] Marguerite Wieler,et al. Midbrain iron content in early Parkinson disease , 2008, Neurology.
[100] N. Hattori,et al. Neuropsychiatric and cognitive features in autosomal‐recessive early parkinsonism due to PINK1 mutations , 2007, Movement disorders : official journal of the Movement Disorder Society.
[101] M. Farrer,et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.
[102] D. Cordato,et al. Dementia with Lewy bodies in an elderly Greek male due to α-synuclein gene mutation , 2006, Journal of Clinical Neuroscience.
[103] A. Singleton,et al. Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques , 2006, Movement disorders : official journal of the Movement Disorder Society.
[104] M. Farrer,et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.
[105] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[106] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[107] M. Cookson,et al. α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[108] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[109] N. Quinn,et al. Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality , 1998, Movement disorders : official journal of the Movement Disorder Society.
[110] V. Dhawan,et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.
[111] D. Eidelberg,et al. [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.
[112] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[113] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[114] J. Jankovic,et al. Variable expression of Parkinson's disease , 1990, Neurology.
[115] T. Joh,et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease , 1990, Annals of neurology.
[116] P. Yates,et al. PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE , 1983, Neuropathology and applied neurobiology.
[117] Dennis W Dickson,et al. Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.
[118] Young Eun Kim,et al. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders. , 2017, Movement disorders : official journal of the Movement Disorder Society.
[119] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[120] Shobini L. Rao,et al. Early onset Parkinson's disease: Are juvenile‐ and young‐onset different? , 1994, Movement disorders : official journal of the Movement Disorder Society.
[121] N. Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[122] K. Jellinger,et al. Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.